EyePoint Pharmaceuticals (EYPT) Reports In-Line Q2 EPS

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 EPS of ($0.52), in-line with the analyst estimate of ($0.52). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $10.89 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Cerebras Q1 EPS miss sends shares down 9% after-hours